Okay. All right, I think we are ready to get started. Thanks everyone for joining us again for this year's Guggenheim Healthcare Innovation Conference, and to day two today. I am Vamil Divan, one of the biopharm analysts here at Guggenheim. Next up in this room, we have Unicycive Therapeutics, and with me I have Shalabh Gupta, the CEO of the company. Thanks for giving us your time and joining us again, Shalabh. Maybe just to kick things off for those who are less familiar with Unicycive, maybe just an overview of the company. Obviously exciting times, important event coming up in a few months, but just a background of the company, where we are right now, and then we will look forward from there.
Yeah. Thank you, Vamil, and thank you to Guggenheim for having us. By way of background, we are a clinical stage biopharma company based in California. We have a lead drug, which is oxylanthanum carbonate, indicated for treatment of hyperphosphatemia in patients who are on dialysis, currently waiting for PDUFA date from the FDA, which is March 25, 2027.
Okay, great. Maybe just talk about this market that you are looking to get into in March. How are patients currently managed? I know there are some other therapies that have been on the market for some time. How are they currently managed with the current agents, and then what is sort of the unmet need that you see in this space right now?
Chronic kidney disease, the last stage of chronic kidney disease is stage 5, which is also called end-stage kidney disease, ESKD, or ESRD, end-stage renal disease. When patients are on dialysis, 80% of these patients need something to manage their phosphate because the dialysis, we are talking hemodialysis primarily, does not take out the phosphate, and phosphate that is present has nowhere to go but combines with the calcium and causes many complications, two being cardiovascular risk, which is increase in mortality and morbidity from heart attack and other cardiovascular complications, and the second is the fractures, increased risk of fractures because again, calcium phosphate combined together get deposited in soft tissue and cause pain as well as fractures. Currently, there are six approved drugs for treatment of hyperphosphatemia.
With the six approved drugs over the last several years, the compliance or the ability to control phosphate has been limited. If you take a more relaxed version, which is 4.5 mg/dL as a target serum phosphate level, you find 44% of U.S. population has not been able to achieve that target serum phosphate level. If you take more stringent number, which is 5.5 mg/dL , other way around, you will get to 75%. So one way or the other, you find that patients are not able to achieve their target serum phosphate level, and that begs the question why.
Yeah.
It all comes down to the problem that exists with the existing treatment. I misspoke. The numbers will be 75% if you take more stringent.
Right.
Yeah.
Okay.
Yeah.
Right. The limitations, maybe you can elaborate on that a little bit more.
Sure.
What are the limitations of the current-
Existing treatment require patients to either take a large number of pills. You would argument patients taking 12- 15 pills per day, or large-size pills. There are large-size pills that are available which are fewer in number, but the large-size pills then come with the baggage of having to chew the pills. The large-size pills require patients to chew the pills, and these pills taste horrible because they are metallic. No matter what we add onto to mask the taste, they taste still metallic, so people don't like to chew the pills, and that is where the compliance becomes a huge challenge.
Okay. That is where OLC comes in. Maybe you can-
Sure
talk to us a little bit about the value proposition that OLC would offer to these patients, and maybe before getting to talking a little bit about the data-
Sure
you have generation date-
Sure
and how this could differentiate from the current agents.
Oxylanthanum carbonate is a proprietary new chemical entity based out of lanthanum. It's dilanthanum dioxycarbonate, and it is a drug that allows patient to be able to take a drug which comes in the form of a small pill. In most recent trial that we ran in patients who are on dialysis, it's a single-arm study that showed roughly 69% patients were able to control their target serum phosphate level by taking one small-size pill, which is a 500 mg pill. It looks very much similar to the size of a baby aspirin. The way this drug is given, this drug is given in a small pill, one pill with each meal to swallow. No need to chew, and it can be just taken with a simple water. The titration of these drugs are based on what the serum phosphate level is for any given patient.
Starting dose for a drug like ours would be 500 mg three times a day and can be titrated up to 1,000 mg three times a day.
Okay. Perfect. Then, you'd mentioned that you have PDUFA date coming up, so maybe you can just talk about the status there in terms of resubmission and kind of any-
Sure
I don't know if there's anything you can share in terms of interactions or
Yeah
what we should expect between now and then at least.
We resubmitted with a second drug product vendor, which was only drug product vendor deficiency was the only deficiency for us to have not gotten our drug approved. FDA has not raised any safety or efficacy risk in the past. The drug product vendor we used is a second drug product vendor that was last inspected in 2024, and they received the highest level of review that you get from FDA, which is no action indicated, NAI status. That resubmission was in September, and that provided a six-month review cycle, so we expect in March. In resubmission, typically there is no mid-cycle review. We would obviously respond to FDA if there is a feedback or question they have, and we work with the agency, and we'll continue to do so. But at the moment, we don't have anything.
We said previously that we don't know if the second vendor, a drug product vendor, does need to be inspected or not. Only FDA can make that decision.
Okay. And you're saying second vendors. Obviously, there was a first vendor.
That's right.
There was some questions we've got from investors too in terms of could that sort of change the timelines or could that be added?
Sure
And maybe you could talk about kind of where that stands at this point.
Big picture, the primary drug product vendor, once they get inspected and they come back in compliance, if all that happens before the PDUFA date, that allows it a potentially shorter timeline. It all depends on how FDA reviews that application and how could we work with the line with FDA. I will call it that is a more of a optionality at the moment. We do not have a visibility in terms of the We will provide details as soon as we can in terms of inspection, but more importantly, even after inspection, the vendor has to come back in compliance, and that takes some time from inspection to the FDA's decision-making. That is number one. Number two is that with regard to approval date, we are working with the base case assumption of March 25th.
Yeah. That is what we should be focused on at the moment.
Sure. That is right.
If something happens.
That's right.
Okay.
That's right. Yeah.
So then, let's kind of move looking forward now. March, assuming we could get through the approval side, can you just talk about sort of how you're thinking about the initial commercial rollout of this product? And then, there's obviously this TDAPA component to that too.
Yeah.
Maybe you can talk about eligibility for OLC within TDAPA.
I will break down this question in three parts. Number one is that how we are thinking of commercial launch from now till March. This particular market is a very concentrated market. The number of physicians that a call point, the drug as historically, this drug or this class of drugs are indicated in patients who are on dialysis. So you are reaching out to patients who are in dialysis centers. I want to make a point that dialysis organizations, which as you know, is a very, very concentrated market. Top three dialysis organizations control roughly 87% of the market. If you take top six, that is 90+% of the market share. That is 40% by Fresenius, 40% by DaVita, the third largest is US Renal Care. So they control in terms of where the dialysis centers are.
Regarding number of physicians that are out there, we have talked about this before. If one were to have 60 sales reps, you can target roughly 80% of those physicians who are primary prescribers for the phosphate lowering therapy. Our ability to address that market is not only upon approval, but about creating market awareness, which we have been doing for some time. This delay allowed us even more time. We were most recently at American Society of Nephrology meeting in Denver. The intention is to be able to show the peer-reviewed publication, which we have, be able to reach out to those thought leaders, explain to them how our drug solves their problem, provide the data which we have generated from clinical trials, so we get that out there. So we are doing all of that. Upon approval, the TDAPA application comes four times a year.
Assuming March 25th approval date, then next TDAPA application will be April 1, which we will be able to file. Our understanding is the review is six months, and that will give the TDAPA approval on October 1st, 2027.
Okay. Just maybe go back to that first part.
Sure.
You mentioned ASN, obviously the biggest meeting of nephrologists. Maybe just share some of the feedback as you've been talking to the doctors, whether there or otherwise, in terms of their interest level.
Physicians are very much looking forward to a treatment option they can give to their patient that solves the problem, and they're excited about it. We had fortuitously, we had the date of PDUFA date of March 25th, so we were able to tell them that this is when we expected to hear back from the FDA, it's a target action date, March 25th. They are very much looking forward to it. The commonest part, Vamil, that we have done, this is a primary market research we did a few years ago, and that continues to be the case. The number one unaided question, if you ask a physician, we did with 100 U.S. nephrologists, I'm repeating the study that we did way back in time. The number one question that when it comes down to hyperphosphatemia is pill burden. It's not efficacy, it's not safety.
Of course, pill burden comes if patients can take fewer pills, then you worry about whether they're safe, will they be tolerating. With a target product profile like ours, we believe there is a huge enthusiasm towards it, and we are looking forward to being able to get the drug out to the patients and through these physicians.
Okay. I guess what else between now and March in terms of other commercial readiness, sales force-wise? What else?
There, again, I divide it into three major buckets, if you will. One is to create infrastructure that is required to be able to launch the drug, and it does not matter what size organization you are, certain things that need to happen. For example, state licenses. Every state requires a pharmacy license. We have been working on that and getting most of the states that we can apply to get the state licenses. Similarly, specialty distribution arrangement. We have been working on a hub, universal hub, which is called UniSource, we call it, named after Unicycive, with the intention of that hub is that if physician writes a prescription, we want to be able to manage the backend logistics that are required for patient to get the prescription filled. Those are which I will call more infrastructure. Second is being able to build the internal team.
We have added some more people this year and last year, but our intention would be to add a few more senior leadership role in the first quarter of next year before approval. The third part that is important to keep in mind is that this is a concentrated market, which we talked about before, but dialysis organizations play a huge role in terms of how the drug gets to the patients.
Yes.
We are talking to all the dialysis organizations. There is a win-win scenario because if we can work with them in a collaborative relationship, they have access to a drug, and the reimbursement environment formula, as you recall, is through TDAPA. Upon TDAPA, Medicare pays for it, and this allows a frictionless access to the patient, especially for Medicare fee-for-service. So we are working with the dialysis organizations to have those agreements. We would be able to talk more about incoming upon approval of before it, but the goal is to be able to establish those long-term relationship with them.
Okay. One other question just sort of came up to me is with TDAPA, you mentioned applying for April 1st.
Sure
getting in hopefully October 1st. Like how quickly did that switch turn on then at the dialysis providers that
Okay
get this part of TDAPA?
Yeah.
Do they start using it on October 2nd, or does it take
Right. A good question. What happens to Conceptually, CMS will put out the notification of OLC now being covered by TDAPA a few days to few weeks before October 1. So in other words, dialysis organizations do get notified. You are asking a good question because what happens on October 1st? So think about two-part answer. One is that from our point of view, we want to get as many patients on oxylanthanum carbonate as possible, even before TDAPA because then October 1st when these patients are eligible for TDAPA, the reimbursement can come from CMS. But CMS The second part to answer your question, logistically, CMS would notify the DOs, dialysis organizations, that OLC is TDAPA eligible. So on October 1st, physicians in the dialysis clinic know that oxylanthanum carbonate, they were to prescribe, this is going to be covered by CMS. It doesn't happen exactly on October 1st.
Our reimbursement from CMS starts on October 1st.
Okay. Okay, that's helpful. Then maybe for those less familiar with TDAPA, so how does that process work then? Assuming you enter TDAPA on October 1st,
Yeah
what's the duration and kind of
Sure
the follow-through from there?
High level, TDAPA stands for Transitional Drug Add-on Payment Adjustment. It was designed to create incentive for new innovative products to come into market. Historically, ESRD bundle payment includes all the drugs, except the phosphate binders were not included. January 1, 2025, this class of drugs went into TDAPA, so now the reset bundle price is there, which will be starting January 1, 2027. That reset bundle price includes all existing phosphate binders. Since our drug did not get approval and was not part of the reset bundle price, CMS allows for an innovative product like ours to be covered for two years of full 100% ASP reimbursement. In other words, for first two years, first 24 months, from whenever that TDAPA designation is given, oxylanthanum carbonate gets 100% average selling price.
After the first two years, after the first 24 months, for the next 36 months, so next three years, it is at a reimbursed 65% average selling price. This is most applicable for Medicare fee-for-service, right? That is 1/3, roughly 1/3 of the market. Another 1/3 of the market that does not get affected by TDAPA is commercial insurance. So that's Blue Cross Blue Shield, Aetna, and there are products on the market that have shown that even commercial market is meaningful, can be meaningful.
Okay. Another question we sometimes get from investors, is this sort of process in TDAPA and any risks to you not getting into TDAPA?
Yeah.
I know based on the NDA filing and all, or maybe just sort of confirm for people kind of the process and-
Yeah
likelihood of
We are highly confident of getting our ability to get TDAPA because TDAPA is there is spelled out criteria to get TDAPA. You have to have a certain type of NDA, and we believe we are type 2 NDA. We can talk about that, and then the drug has to be approved. Then you apply, it is an online application. It is essentially applying for those investors who are familiar with J-code. It is like applying for J-code, which is a type of reimbursement code that happens for other products. But in this particular condition, which is a ESRD bundle payment, TDAPA application is somewhat similar to in that it is an online form. You apply it, and CMS has the ability to grant it
Okay
to you.
You mentioned the two-year period and then three years following
Sure
the 65%.
Yeah.
How are you thinking about pricing or the commercial opportunity beyond TDAPA once that five-year period ends?
Yeah. I think, just want to say the first two years of TDAPA provide an opportunity for patients to benefit from the drug, for physician to be able to prescribe the drug, and the pricing is not as, it depends on the manufacturer. We haven't given specific guidelines, but we've talked about it. The most expensive product that has been on the market is XPHOZAH. That is a WAC cost. Price is around $41,000 per patient per year. After that has been AURYXIA and VELPHORO is around $25,000-$26,000 per patient per year. I can't specifically comment on the pricing of our drug, but the first two years you have that ability to get reimbursement, then another three years at a 65%. What I envision, what we are thinking about is to have a longer term contract with the dialysis organization.
Our belief is that if we do it properly, the company and the product makes money not only the first two years followed by three years, but also much longer than that. The question, the logical question, why would that be? That comes back to the clinical profile of the drug. We believe we have an ability to lower down the pill burden, which we talked a fair bit about. The ability to have a drug that can lower the pill burden, but also address the serum phosphate level allows us to have those longer-term contracts. We can talk more specifically once the contracts are signed. We can talk more openly about it after the execution of these contracts. But the intention is that everybody wins. The dialysis organizations win because we have a long-term contract.
Number two, the company obviously wins because we have not only the two plus three years, but also much longer-term visibility. The last part is that it also allows physicians to be confident if they write a prescription. You recall from your being a physician background.
Yeah
Physicians sometimes they want to be able to do the right thing by the patient, but they also worry, will the drug be covered by the insurance? So, having TDAPA allows that for two plus three years, but then if we can have a longer-term relationship with the dialysis organization, we believe everybody wins. So, that's our intention in terms of how we are thinking about.
Okay. No, that's great. Then one other question we get from investors, aside from the products that are already on the market, there's a little bit of word from other competitors in terms of moving into the space.
Sure.
Just how are you seeing this sort of landscape around the hyperphosphatemia market evolve?
Nothing in a very immediate to near term. I can define that immediate near term is more like if October 1, 2027 is a TDAPA designation. We believe the next most competitive product that we are aware of is Alebund's drug. They have two drugs, AP301, and the other one is the pan-inhibitor. Given the regulatory stage that they are in, we can't comment on somebody else's path. We feel that in the near term, there is nothing in the market that comes in. Much longer term, there are other products that could come in the market. Answer is yes, potentially yes, but the time will tell how they fare and what the clinical profile looks like, and regulatory timeline for them. But in the near term, to the best of our knowledge, there is nothing that competes with oxylanthanum carbonate.
Okay. Okay, great. Then maybe switching over to more of a corporate side here.
Sure.
The one thing very unique I think about the Unicycive story is this dividend policy. Maybe you can just explain that to investors and how that works.
The intention of giving dividend to investors was that during TDAPA period, company generates a lot of free cash. The idea was that typically in a company, the stock price appreciation is the one way that investors capture upside. But we felt that it is not the only way. You don't have to necessarily buy or sell the stock. We have this 75% of dividend, which is a 75% of free cash flow when the company becomes profitable, that we plan to give it to all shareholders as the date of that dividend whenever that is announced. That way, the investors have ability to capture upside, not just by having to buy or sell the stock, but also having the dividend that comes back to them.
Okay. And I think your latest guidance is for cash through second, into second half of next year.
Yeah.
How should we think about the need to finance this launch and all the activities that you're talking about?
At the moment, we are sufficiently funded, Vamil. We reported $61.4 at the end of Q2. We'll be reporting Q3 very near term. We have ability to be able to launch the drug. We also have those warrant tranches, which at the moment is not worth mentioning because time will tell. They have a time-bound limitation, but they have a set stock price, the trigger price, but also set duration. So we feel we have more than sufficient cash to be able to launch the drug. As we go there and how we think about it, we'll see. But we don't need to go raise money in any time near term to be able to launch the drug. When we said second half, it's difficult to guide the whole year because launches are always can take more money than less, and you want to be thoughtful about it.
But we feel sufficiently capitalized at the moment.
Okay. Then just maybe again, looking at from a catalyst perspective, obviously March 25th is the key
Yeah
key event without question. What else are we looking out for from the company over the next 12, 18 months?
Approval, partnership, potential partnership with a dialysis organization, being able to launch, getting TDAPA. Those are the catalysts that we expect. I mean, approval is the first one.
Yeah, yeah.
And then partnership with dialysis organization, getting a TDAPA designation. I think these are all a lot of exciting milestones ahead of us. I think the drug with the clinical profile we have, one of the questions that you asked earlier at ASN, we feel quite positively surprised that physicians, when they say the commonest feedback is that it's a no-brainer. "Doctor, this is something we would like to prescribe to our patients." So we feel there is an opportunity to do well for patients, physicians, as well as for our investors.
Yeah. Okay. That's great. Why don't we leave it there? Thanks again for joining us. Good luck over these next few months as we work towards the-
Thank you very much for having us
PDUFA date, and we'll see how the progress goes.
Thank you.
Thank you.
Thank you very much.
Thanks.